IMNM Relative Valuation
IMNM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IMNM is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for IMNM's competitors is 117.99, providing a benchmark for relative valuation. Immunome Inc Corp (IMNM) exhibits a P/S ratio of 539.86, which is 357.55% above the industry average. Given its robust revenue growth of 184.35%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
People Also Watch
DXYZ
Destiny Tech100 Inc
40.890
USD
-0.85%
GNK
Genco Shipping & Trading Ltd
13.950
USD
-0.57%
SMLR
Semler Scientific Inc
41.880
USD
-3.21%
ODC
Oil-Dri Corporation of America
48.370
USD
+0.08%
LENZ
LENZ Therapeutics Inc
28.730
USD
+0.98%
LPRO
Open Lending Corp
2.050
USD
-1.91%
CAPR
Capricor Therapeutics Inc
11.010
USD
+6.17%
MGIC
Magic Software Enterprises Ltd
15.805
USD
-2.14%
PLPC
Preformed Line Products Co
137.800
USD
-0.91%
EU
enCore Energy Corp
1.600
USD
0.00%
FAQ
Is Immunome Inc (IMNM) currently overvalued or undervalued?
Immunome Inc (IMNM) is now in the Overvalued zone, suggesting that its current forward PS ratio of 539.86 is considered Overvalued compared with the five-year average of 63.51. The fair price of Immunome Inc (IMNM) is between 1.73 to 4.78 according to relative valuation methord. Compared to the current price of 8.56 USD , Immunome Inc is Overvalued By 78.94% .
What is Immunome Inc (IMNM) fair value?
How does IMNM's valuation metrics compare to the industry average?
What is the current P/B ratio for Immunome Inc (IMNM) as of May 21 2025?
What is the current FCF Yield for Immunome Inc (IMNM) as of May 21 2025?
What is the current Forward P/E ratio for Immunome Inc (IMNM) as of May 21 2025?